![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS
IN PATIENTS WITH HIV/HCV CO-INFECTION
|
|
|
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
Jurgen K Rockstroh1, Marc-Antoine Valantin2, Josep Mallolas3, Massimo Puoti4, Juan A Pineda5, Patrick Ingiliz6, Fenglei Huang7, Richard Vinisko7, Douglas Dieterich8
1University of Bonn, Bonn, Germany; 2Hopital Pitie-Salpetriere, Paris, France; 3Hospital Clinic-University of Barcelona, Barcelona, Spain; 4AO Ospedale Niguarda Ca' Granda Milano, Milan, Italy; 5Hospital Universitario de Valme, Seville, Spain; 6Medical Center for Infectious Diseases, Berlin, Germany; 7Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 8Mount Sinai Medical Center, New York, NY, USA
![CROI1.gif](../images/032114/032114-6/CROI1.gif)
![CROI2.gif](../images/032114/032114-6/CROI2.gif)
![CROI3.gif](../images/032114/032114-6/CROI3.gif)
![CROI4.gif](../images/032114/032114-6/CROI4.gif)
![CROI5.gif](../images/032114/032114-6/CROI5.gif)
![CROI6.gif](../images/032114/032114-6/CROI6.gif)
![CROI7.gif](../images/032114/032114-6/CROI7.gif)
![CROI8.gif](../images/032114/032114-6/CROI8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|